devices, tools, and enabling technologies”, but will look at investments more broadly across healthcare. Aberman was at Regeneron for seven years, rising to the role of senior vice president of ...

Boston Scientific makes surgical devices and medical equipment to treat ... due to wholesaler destocking. Regeneron Pharmaceuticals makes drugs to treat eye diseases, allergies, inflammation ...

Contributors to performance Boston Scientific makes surgical devices and medical equipment ... due to wholesaler destocking. Regeneron Pharmaceuticals makes drugs to treat eye diseases, allergies ...

It provides a range of software, services, and devices for ... decision regarding the Eylea biosimilar case as a modest setback but believes it does not overshadow Regeneron’s long-term growth ...

Cell therapy is emerging as a cutting-edge precision treatment in ophthalmology and is gaining immense popularity worldwide among people affected by degenerative eye diseases. Traditional therapies ...

Eylea, which Regeneron Pharmaceuticals ... The MedTech segment includes an elaborate range of medical devices and products used in cardiovascular intervention, orthopedic, interventional solutions ...

The Eylea franchise was in need of a win after an appellate court last week denied the pharma’s bid to block Amgen’s ...

Unity Biotechnology’s investigational eye treatment failed to match Eylea at 20 weeks—part of the mid-stage trial’s primary ...